Novavax Company Profile (NASDAQ:NVAX)

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Monday, May, 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.02. The firm earned $5.68 million during the quarter, compared to analyst estimates of $6.17 million. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. Novavax's revenue was up 34.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.29) EPS. View Novavax's Earnings History.

9 brokerages have issued 1 year price objectives for Novavax's shares. Their forecasts range from $1.00 to $25.00. On average, they expect Novavax's stock price to reach $5.71 in the next year. View Analyst Ratings for Novavax.

Here are some recent quotes from research analysts about Novavax stock:

• 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (6/10/2017)
• 2. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)
• 3. Cantor Fitzgerald analysts commented, "RSV maternal vaccination likely primary value driver in 2017. We believe investors will be keenly focused on the RSV vaccine when used in the context of maternal vaccination, particularly given the failure of the elderly subject RSV pivotal trial late last year. Clinical data suggest that the vaccine is immunogenic in pregnant women and that anti-RS F protein antibodies are efficiently transferred across the placenta to the fetus." (1/12/2017)
• 4. Piper Jaffray Companies analysts commented, "So, Now What?" (9/16/2016)

Novavax saw a decrease in short interest in the month of June. As of June 30th, there was short interest totalling 56,851,825 shares, a decrease of 11.6% from the June 15th total of 64,277,879 shares. Based on an average daily volume of 6,096,592 shares, the days-to-cover ratio is currently 9.3 days. Currently, 20.4% of the company's stock are short sold.

Some companies that are related to Novavax include Arena Pharmaceuticals (ARNA), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA), Crispr Theraptc (CRSP), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), Mesoblast Limited (MESO), Intellia Therapeutics (NTLA), ANI Pharmaceuticals (ANIP), ImmunoGen (IMGN), WAVE Life Sciences (WVE), Cara Therapeutics (CARA), Agenus (AGEN), AC Immune SA (ACIU), Inovio Pharmaceuticals (INO), Adamas Pharmaceuticals (ADMS), Abeona Therapeutics (ABEO) and PDL BioPharma (PDLI).

Novavax's management team includes the folowing people:

• James Francis Young Ph.D., Independent Chairman of the Board
• Stanley C. Erck, President, Chief Executive Officer, Director
• Barclay A. Phillips, Chief Financial Officer, Senior Vice President, Treasurer
• Gregory M. Glenn M.D., President, Research and Development
• John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary
• John J. Trizzino, Senior Vice President - Commercial Operations
• James F. Cummings, Vice President - Clinical Development and Translational Medicine
• Rajiv I. Modi Ph.D., Director
• Gail Koziara Boudreaux, Independent Director
• Richard H. Douglas Ph.D., Independent Director

Novavax's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Creative Planning (0.17%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Novavax's stock was bought by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Novavax stock can currently be purchased for approximately $1.51.